KONSORTIUM mRNA
Partner
University of Leipzig
As part of KmR, participating scientific groups from the University of Leipzig contribute expertise in lipid synthesis (Dr. Wölk), peptide development (Prof. Lamers) and computer-aided drug development as well as structural biology (Prof. Meiler and Dr. Künze), which enables the development of new ones Special lipids and lipid formulations are possible.
The University of Leipzig and the Institute for Drug Development expect the collaboration to make a relevant contribution to the further development of mRNA-lipid nanoparticles. Furthermore, it is of interest for a location in the training of pharmacy students to train specialized scientists in the field of this new technology as part of this project consortium, which will be of great interest to the pharmaceutical industry.
Institute for Drug Development
The Institute for Drug Development at the University of Leipzig integrates innovative, computer-aided approaches for therapy design and drug discovery with experimental validation and optimization. The institute’s team is working with scientists in Leipzig and around the world to use these new algorithms to address urgent challenges to human health including cancer, infectious diseases such as influenza or HIV; Illnesses that affect the brain such as schizophrenia or addictions as well as cardiac arrhythmias or obesity.
The Institute for Drug Development consists of the departments of Pharmaceutical Chemistry, Pharmaceutical Biology and other research groups for “Vaccines and Antibodies”, “Computational Structural Biology”, “Immunogens”, “Biomolecular EPR Spectroscopy”, “peptide chemistry” and “organic drug synthesis”.